ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pegozafermin

Also written as “Pegozafermin” and “BIO89-100”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Hypertriglyceridemia, led by 2 companies.

Drug pagePegozafermin: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 2, 20238 company-led studies, 3 open or runningAcquisition: Roche acquired 89bio, Oct 2025Next primary completion: Mar 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
89bioits history only50 open or runningphase 3since May 2, 2023Aug 4, 2019none ahead
Hoffmann-La Roche33 open or runningphase 3since Mar 13, 2024Mar 13, 2024Mar 2, 2027phase 1 · NCT07835243
  • Named in Hoffmann-La Roche’s own pipeline as RG6881 pegozafermin, phase 3, as of Oct 22, 2026 (source).

Also a collaborator on its studies: ProSciento.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2022Named pegozaferminINNProposed as its International Nonproprietary Name in WHO's List 127 · before, BIO89-100
  2. Mar 13, 2024First study: phase 3 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT06318169 · 1,350 planned · United States, Argentina, Australia and more
  3. May 14, 2024Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT06419374 · 1,800 planned · United States, Argentina, Australia and more
  4. Oct 30, 2025Roche acquired 89bioAcquisitionWith it pegozafermin, its lead asset · completed · Roche (release filed with the SEC)
  5. Sep 17, 2026Phase 1 study in Healthy VolunteersNCT07835243 · 105 planned

Ahead

  1. Mar 2, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07835243
  2. Jun 30, 2028Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT06419374
  3. Feb 2029Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT06318169

TargetBeta

“A glycopegylated form of fibroblast growth factor 21 (FGF21), with metabolic regulating, anti-diabetic, anti-lipidemic, and anti-fibrotic activities. Upon administration, pegozafermin mimics FGF21, and binds to FGF21-specific receptors, FGFR1c, FGFR2c, and FGFR3c, in the liver and adipose tissue.…”NCIt, read by Claude

Other programs on FGF21

ProgramCompanyFurthest phaseStudies
efimosfermin alfaGlaxoSmithKlinephase 310
efruxiferminNovo Nordiskphase 36
zalferminNovo Nordiskphase 210

Studies

All 3 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07835243Healthy Volunteers1Not yet recruitingMar 2, 2027105
NCT06419374Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3RecruitingJun 30, 20281,800
NCT06318169Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3RecruitingFeb 20291,350

How it is read

Names in the registry

  • “Pegozafermin”, 6 entries
  • “BIO89-100”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.